trial

Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

NCTId NCT02724917
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Suspended
Enrollment 30 (estimated)
Sponsored by CoMentis
Primary completion 2016-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Suspended
Enrollment
30 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2016-04
Primary completion
2016-09
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
APN1125

Sponsors

CoMentisLead Sponsor
Alpharmagen, Inc.Collaborator

Investigators

1
David P Walling, PhDPrincipal Investigator

Sites

1 total
Long Beach, United States

Linked catalysts

1
Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophr — primary completion2016-09

Facts & assertions

4 sourced
Enrollment
30
Phase
PHASE1,PHASE2
Primary Completion Date
2016-09
Status
SUSPENDED
relationships
The graph out of here
drug
APN1125
drug
lead_sponsor
CoMentis
company
collaborator
Alpharmagen, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
David P Walling, PhD
person